Long Acting Stimulants in Children Under Six Years of Age

* Note: The 2014-2015 ADHD Medication Guidelines for Children and Adolescents are specifically written to support Florida Medicaid providers and include a preschool (children less than 6 years of age) guideline. This guideline may be accessed at: http://medicaidmentalhealth.org/ViewGuideline.cfm?GuidelineID=44

LENGTH OF AUTHORIZATION:
Initial Review: 3 months
Continuation of therapy: 6 months

CLINICAL NOTES
According to the American Academy of Pediatrics Clinical Practice Guideline for the Evaluation and Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), evidence based parent and/or teacher administered behavior therapy is the first line of treatment for preschool age children who are 4 to 5 years of age. These guidelines go on to state that many young children with ADHD might still require medication to achieve maximum improvement, and medication is not contraindicated for children 4 through 5 years of age. There are limited clinical studies in this age group with most of the evidence based data surrounding the use of methylphenidate preparations.

INITIAL REVIEW CRITERIA:

1. Patient has had an adequate trial of parent training or teacher administered behavioral therapy and has persistent moderate to severe dysfunction as defined by:
   a. Symptoms that have persisted for at least 9 months
   b. Dysfunction that is manifested in both the home and other settings such as preschool or child care

2. Trial and failure of a preferred short acting methylphenidate should be submitted prior to consideration of a long acting agent.

3. Authorization request is for a preferred long acting methylphenidate preparation or the provider has submitted documentation of trial and response to therapy of a preferred methylphenidate preparation.

4. Patient’s ability to swallow whole tablets/capsules should be assessed, if patient is unable to swallow whole tablets/capsules and also requires a long acting agent, choices should be limited to those preparations which may be utilized as a sprinkle cap or a liquid or a transdermal patch including:
   a. Ritalin LA, Metadate CD/ generic equivalents
   b. Quillivant XR powder for suspension
c. Daytrana transdermal patch
d. Focalin XR/generic equivalent
e. Dexedrine spansule/generic equivalent
f. Vyvanse

CONTINUATION OF THERAPY
1. Patient continues to meet initial review criteria
2. Documentation supports response of target symptoms with medication

Note: The long acting agents for children less than 6 years old that require review include, but are not limited to:
- Ritalin LA/Metadate CD/Aptensio XR/generic equivalents
- Concerta/Metadate ER/Methylin ER/generic equivalents
- Ritalin SR/generic equivalent
- Adderall XR/generic equivalent
- Daytrana
- Quillivant
- Focalin XR
- Vyvanse
- Dexedrine spansule/generic equivalent

---
